In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with ...

While AMT-130 could result in meaningful revenue for ClearPoint, the Huntington's opportunity is relatively modest compared ...

Universities must do more to provide students with cell and gene therapy manufacturing skills, according to a new study.

New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with ...

Cirrus’ lead program is a novel AAV gene therapy designed to restore IRAK-M, a central regulator of the eye’s immune homeostasis, so as to ...

French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

In a preclinical study, UC Davis Comprehensive Cancer Center scientists have developed a highly targeted gene therapy that ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

Stunning success in halting Huntington's disease with gene therapy offers new hope to those with the disorder—and potential ...

From cancer biology to proactive health management, customized care is changing patient outcomes, but what are the costs and ...

A one-time gene therapy called AMT-130 helped slow the progression of Huntington's disease by 75%, paving the way for the ...